GeoPharma gets license for pulmonary hypertension compound

By Angela McDaniels

Seattle, Jan. 31 - GeoPharma Inc. said it has obtained a license from The University of Florida Office of Technology Licensing to develop the university's novel therapeutic for the treatment of primary or idiopathic pulmonary hypertension.

"The in-licensing of this compound follows our strategy of developing novel therapeutics for niche markets with high barriers to entry. We have demonstrated the ability to both develop research in-house, as well as identify external research with commercial potential," president Kotha Sekharam said in a company news release.

The efficacy of the synthetic peptide has been established through in vitro data and studies of animal lung models, the company said. Further studies are in progress and a patent on the compound has been filed.

Pulmonary hypertension is a disorder in which the small pulmonary arteries constrict or become blocked. People with the disorder generally develop it in their 30s and suffer a mortality rate greater than 30% over four years, according to the release.

GeoPharma is a pharmaceutical company based in Largo, Fla., that manufactures and distributes over-the-counter, nutritional, generic drug and functional food products.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.